ecrin-mdr-crcClinical2020Solid TumorCarcinoma, Transitional CellHead and Neck CancerColorectal CancerUrothelial CarcinomaPancreatic CancerHead and Neck NeoplasmsNeoplasm MetastasisColon cancerColorectal NeoplasmsSolid tumorsPancreatic NeoplasmsMetastatic CancerSolid TumorCarcinoma, Transitional CellColorectal CancerUrothelial CarcinomaHead And Neck NeoplasmsPancreatic CancerNeoplasm MetastasisColon CancerColorectal NeoplasmsHead And Neck CancerPancreatic NeoplasmsMetastatic CancerSolid TumorsInterventionalhttps://newmdr.ecrin.org/Study/2360612United States12GemcitabineBile duct cancerPaclitaxelTislelizumabCombination therapyECRIN MDRRecruitingfalseLYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid TumorsA Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors2020-12-152360612NCT04666688